In vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia

Hematological Oncology

Volumn 24, Issue 3, 2006, Pages 151-158

  Li, XiaoQing ^a   Lu, Yue ^a   Huang, WenLin ^a   Xu, HaiPeng ^a   Chen, XiaoQin ^a   Geng, QiRong ^a   Fan, Huijie ^a   Tan, YinDuo ^a   Xue, Gang ^b   Jiang, XiangLi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Adenoviral vector; BMSCs; Gene therapy; hIFN

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL GENE THERAPY; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; APOPTOSIS; BONE MARROW CELLS; COCULTURE TECHNIQUES; FEMALE; GENE THERAPY; HUMANS; INTERFERON-GAMMA, RECOMBINANT; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; MALE; MESENCHYMAL STEM CELLS; S PHASE; STROMAL CELLS; TRANSDUCTION, GENETIC;

EID: 33749242422     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.779     Document Type: Article

References (36)

1. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-74. DOI: 10.1126/ science.276.5309.71.
2. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147. DOI: 10.1126/science.284.5411.143.
3. Almeida-Porada G, Porada CD, Tran N, Zanjani ED. Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood 2000; 95: 3620-3627.
4. Liechty KW, MacKenzie TC, Shaaban AF, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6: 1282-1286.
5. Shi D, Reinecke H, Murry CE, Torok-Storb B. Myogenic fusion of human bone marrow stromal cells, but not hematopoietic cells. Blood 2004; 104: 290-294. DOI: 10.1182/blood-2003-03-0688.
6. Majumdar MK, Thiede MA, Mosca JD, et al. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998; 176: 57-66.
7. Devine SM, Bartholomew AM, Mahmud N, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29: 244-255.
8. Rombouts WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003; 17: 160-170. DOI: 10.1038/sj.leu.2402763.
9. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999-3001. DOI: 10.1182/blood-2002-06-1830.
10. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
11. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729. DOI: 10.1182/blood-2002-07-2104.
12. Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896.
13. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48.
14. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-3844. DOI: 10.1182/blood-2003-04-1193.
15. Lazarus H, Curtin P, Devine S, et al. Role of mesenchymal stem cells (MSC) in allogeneic transplantation: early phase I clinical results (abstract). Blood 2000; 392: 1691.
16. Frassoni FLM, Bacigalupo A, Gluckman E, et al. Expanded mesenchymal stem cells (MSC), confused with HLA identical hemopoietic stem cell transplants, reduce acute and chronic graft versus host disease: a matched pair analysis (abstract). Bone Marrow Transplant 2002; 29: 75.
17. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 1996; 87: 4149-4157.
18. Marini FC, Studeny M, Zompetta C, Zoltick Ph, Wilson JM, Andreeff M. Mesenchymal stem cells (MSC) delivering localized regulated interferon-alpha 2b (IFNα) into the bone marrow as targeted therapy for chronic myelogenous leukemia. Mol Ther 2002; 5(Suppl.): 442.
19. Min YH, Li GX, Jang JH, et al. Long-term bone marrow culture-derived stromal fibroblasts as a potential target for gene therapy in acute myelogenous leukemia. Leuk Res 2002; 26: 369-376.
20. Bartholomew A, Patil S, Mackay A, et al. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001; 12: 1527-1541.
21. Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res 2002; 62: 3603-3608.
22. Eliopoulos N, Al-Khaldi A, Crosato M, et al. A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther 2003; 10: 478-489. DOI:10.1038/sj.gt.3301919.
23. Kurozumi K, Nakamura K, Tamiya T, et al. BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. Mol Ther 2004; 9: 189-197. DOI: 10.1016/j.ymthe.2003.10.012.
24. Stagg J, Lejeune L, Paquin A, Galipeau J. Marrow stromal cells for Interleukin-2 delivery in cancer immunotherapy. Hum Gene Ther 2004; 15: 597-608.
25. Shankaran V, Schreiber RD. Interferon-γ: Basic principles and clinical applications. In Principles and practice of the biologic therapy of cancer, Rosenberg SA (ed.). Lippincott Williams & Wilkins: Philadelphia, 2000; 286-301.
26. Schreiber RD, Celada A. Molecular characterization of interferon-gamma as a macrophage activating factor. Lymphokines 1985; 11: 87-118.
27. Adams DO, Hamilton TA. The cell biology of macrophage activation. Annu Rev Immunol 1984; 2: 283-318.
28. Griffith TS, Wiley SR, Kubin MZ, et al. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999; 189: 1343-1354.
29. Coughlin CM, Salhany KE, Gee MS, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998; 9: 25-34.
30. Kurzrock R, Talpaz M, Kantarjian H, et al. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 1987; 70: 943-947.
31. Budak-Alpdogan T, Alpdogan O, Akoglu T. Morphological and functional characteristics of short-term and long-term bone marrow cultures in chronic myelogenous leukemia. Am J Hematol 1999; 62: 212-220.
32. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998; 9: 2577-2583.
33. Lee K, Majumdar MK, Buyaner D, et al. Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther 2001; 3: 857-866. DOI: 10.1006/ mthe.2001.0327.
34. McGlave P, Mamus S, Vilen B, Dewald G. Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. Exp Hematol 1987; 15: 331-335.
35. Jedema I, Barge RM, Willemze R, Falkenburg JH. High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment. Leukemia 2003; 17: 576-584. DOI: 10.1038/sj.leu.2402844.
36. Grander D, Xu B, Wang P, Einhorn S. Gamma-IFN induced cell adhesion in chronic myelogenous leukemia cells. Leukemia 1994; 8: 299-304.